Humira Competitors Don’t Guarantee Lower Patient Drug Costs

The introduction of seven alternatives to AbbVie Inc.‘s blockbuster drug Humira in July will be the most important test to date on whether market competition can bring down what patients pay for expensive biologics, advocates and drug pricing analysts say.

The wave of biosimilars for the anti-inflammatory treatment, which can cost more than $80,000 annually, marks the most competitors to date for a single biologic drug in the US. Drug pricing analysts and researchers predict other brand-name biologic makers could use this model to avoid government price negotiations under the Inflation Reduction Act. The law allows companies to avoid negotiations ...